Norditropin Flexpro (Somatropin)

Somatropin mimics the natural human growth hormone by binding to growth‑hormone receptors on target cells. This triggers intracellular signaling that increases insulin‑like growth factor‑1 (IGF‑1) production, stimulates protein synthesis, enhances lipolysis, and promotes linear bone growth, thereby restoring growth and metabolic balance.

The dose of Norditropin Flexpro is individualized by the prescribing clinician based on factors such as the patient’s age, weight, IGF‑1 levels, and specific indication. Physicians adjust the regimen during follow‑up visits to achieve optimal growth response while monitoring safety parameters.

Safety data for somatropin during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare professional.

To order Norditropin Flexpro, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Norditropin Flexpro is a recombinant human growth hormone formulated as a ready‑to‑use injection solution, offering convenient subcutaneous administration. Compared with some other brands, it provides a flexible dosing pen system and is manufactured under EU GMP standards, ensuring high purity and consistent bioactivity.

Norditropin Flexpro should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Once in use, follow the manufacturer’s guidance on in‑use stability and discard after the indicated period.

The product is administered by subcutaneous injection, typically using a pre‑filled pen or syringe. The injection site is rotated among the abdomen, thigh, or upper arm to minimise local irritation. Administration technique and timing are determined by the prescribing clinician.

Serious risks include intracranial hypertension, slipped capital femoral epiphysis, severe allergic reactions such as anaphylaxis, and abnormal glucose metabolism that may lead to diabetes. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Norditropin Flexpro is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients for whom growth hormone therapy is not indicated. Caution is also advised for those with uncontrolled diabetes, severe obesity, or chronic systemic illnesses unless specifically approved by a physician.